Search results
Results from the WOW.Com Content Network
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Management of prostate cancer. Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination.
Haptoglobin (abbreviated as Hp) is the protein that in humans is encoded by the HP gene. [5][6] In blood plasma, haptoglobin binds with high affinity to free hemoglobin [7] released from erythrocytes, and thereby inhibits its deleterious oxidative activity. Compared to Hp, hemopexin binds to free heme. [8]
Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [ 8 ] [ 9 ] [ 10 ] [ 15 ] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer.
Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [ 8 ][ 4 ][ 5 ][ 9 ][ 10 ] It is specifically approved to treat non- metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical ...
Sipuleucel-T is indicated for the treatment of metastatic, asymptomatic or minimally symptomatic, metastatic castrate-resistant hormone-refractory prostate cancer (HRPC). Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (AIPC). This stage leads to mCRPC with lymph node involvement and distal ...
94 million men affected globally (2019) [ 3 ] Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. [ 1 ] Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. [ 1 ]
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...